Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T18:05:06.463Z.
Consensus retrieved: 2026-10-06T15:44:06.229Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T18:05:06.463Z.
Quote observation: 2026-10-06T18:00:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a212b8c45fb170636f79061a8993a9d466e21915543081357b5b59dac86f944c
FORWARD PE RATIO
N/A
Avita Medical Inc.
Market Cap
$318.87M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Avita Medical Inc. (RCEL) | $318.87M | N/A |
| Agenus Inc. (AGEN)vs › | $318.77M | 28.62 |
| ClearPoint Neuro, Inc. (CLPT)vs › | $320.14M | N/A |
| Sanara MedTech Inc. (SMTI)vs › | $321.74M | 184.20 |
| Cabaletta Bio, Inc. (CABA)vs › | $321.77M | N/A |
| C4 Therapeutics, Inc. (CCCC)vs › | $312.35M | N/A |
| CapsoVision, Inc. (CV)vs › | $326.26M | N/A |
| Mobia Medical, Inc. Common Stock (MOBI)vs › | $302.90M | N/A |
| Benitec Biopharma Inc. (BNTC)vs › | $301.99M | N/A |
| Larimar Therapeutics, Inc. (LRMR)vs › | $291.39M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
Consensus estimates for this stock are reported in USD, while the share price trades in USD — so per-fiscal-year implied multiples can't be computed honestly here. The analyst estimates table shows the consensus figures with their correct currency label.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
